Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000771257
Ethics application status
Not yet submitted
Date submitted
1/09/2009
Date registered
7/09/2009
Date last updated
7/09/2009
Type of registration
Prospectively registered

Titles & IDs
Public title
A Prospective Randomized Trial Comparing Endoscopic Submucosal Dissection(ESD) and Surgery for Early Stage Esophageal Cancer
Scientific title
A Prospective Randomized Trial Comparing Survival between Endoscopic Submucosal Dissection(ESD) and Surgery for Early Stage Esophageal Cancer
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
esophageal cancer 243614 0
Condition category
Condition code
Cancer 239909 239909 0 0
Oesophageal (gullet)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Endoscopic submucosal dissection (ESD) is an advanced technique of therapeutic endoscopy for superficial gastrointestinal neoplasms. Three steps characterize it:injecting fluid (several fluids such as saline, glycerol and hyaluronic acid are usually combined with diluted epinephrine) into the submucosa to elevate the lesion,cutting the surrounding mucosa of the lesion, and dissecting the submucosa beneath the lesion.
The amout of fluid varies according to the size of cancer and the amount is appropriate when the fluid injected can make the cancer safe enough for endoscopists to cut it off.
This is a one-off treatment and the duration of ESD itself often varies from one hour to 3 hours.
Intervention code [1] 241201 0
Treatment: Surgery
Intervention code [2] 241202 0
Treatment: Other
Comparator / control treatment
Surgery treatment for early esophageal cancer is actually esophagectomy.
Esophagectomy is the removal of a segment of the esophagus; as this shortens the length of the remaining esophagus, some other segment of the digestive tract (typically the stomach or part of the colon) is pulled up to the chest cavity and interposed.
This is a one-off treatment and the duration of esopagectomy itself often varies from 2 hours to 3 hours.
Control group
Active

Outcomes
Primary outcome [1] 240694 0
Survival rate :1,2 , 3 years after treatment. This outcom will be assessed by health care professionals through telephones or by letters.
Timepoint [1] 240694 0
participants will be followed up once each year for 3 years after ESD or surgery through out the study.
Secondary outcome [1] 257333 0
Complication rate. This outcome will be assessed through monitoring by health care professionals .
Timepoint [1] 257333 0
at 1month and 1 year after treatment
Secondary outcome [2] 257334 0
Complete ressection rate assessed through monitoring by health care professionals .
Timepoint [2] 257334 0
at 7 days after treatment
Secondary outcome [3] 257335 0
Quality of life(QOL) assessed by questionnaires.
Timepoint [3] 257335 0
at 1month and 1 year after treatment
Secondary outcome [4] 257336 0
average length of stay assessed by hospital records.
Timepoint [4] 257336 0
at discharge (post-initial intervention).

Eligibility
Key inclusion criteria
1.early esophageal cancer diagnosed by both gastroscopy and pathological examination.
2.lesion to be mucosal or submucosal by endoscopic ultrasound( EUS).
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1.remote metastasis by computed tomography(CT),magnetic resonance imaging(MRI) or positron emission tomography (PET). 2.after treatment of endoscopic electrocoagulation,laser,Argon gas,microwave,endoscopic mucosal resection(EMR) or repeated biopsy in the same lesion.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Each patient enrolled in the study will be given a serial number and will be randomized in blocks to one of the two groups:ESD and surgery. Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation by using a randomization table created by a computer software
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/12/2009
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
80
Accrual to date
Final
Recruitment outside Australia
Country [1] 1967 0
China
State/province [1] 1967 0
Beijing

Funding & Sponsors
Funding source category [1] 237560 0
Self funded/Unfunded
Name [1] 237560 0
Country [1] 237560 0
China
Primary sponsor type
Individual
Name
Linghu Enqiang
Address
28 Fuxing Road,Beijing,100853,China. digestive endoscopic centre gastroenterologic and hepatologic dept. Chinese People's Liberation Army(PLA) general hospital
Country
China
Secondary sponsor category [1] 237037 0
Individual
Name [1] 237037 0
Chu Xiangyang
Address [1] 237037 0
28 Fuxing Road,Beijing,100853,China.
the Thoracic Surgery Department
Chinese People's Liberation Army(PLA) general hospital
Country [1] 237037 0
China

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 243692 0
Institute Ethics Committee,Chinese People's Liberation Army (PLA) general hospital
Ethics committee address [1] 243692 0
Ethics committee country [1] 243692 0
China
Date submitted for ethics approval [1] 243692 0
07/09/2009
Approval date [1] 243692 0
Ethics approval number [1] 243692 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 30103 0
Address 30103 0
Country 30103 0
Phone 30103 0
Fax 30103 0
Email 30103 0
Contact person for public queries
Name 13350 0
Linghu Enqiang
Address 13350 0
28 Fuxing Road,Beijing,100853,China.
digestive endoscopic centre
gastroenterologic and hepatologic dept.
Chinese PLA general hospital
Country 13350 0
China
Phone 13350 0
+86 10 6818 2255
Fax 13350 0
+86 10 6815 4653
Email 13350 0
[email protected]
Contact person for scientific queries
Name 4278 0
Linghu Enqiang
Address 4278 0
28 Fuxing Road,Beijing,100853,China.
digestive endoscopic centre
gastroenterologic and hepatologic dept.
Chinese PLA general hospital
Country 4278 0
China
Phone 4278 0
+86 10 6818 2255
Fax 4278 0
+86 10 6815 4653
Email 4278 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.